Harvard Bioscience Inc (HBIO) stock
HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3017% above fair value
$9.00−0.08 (-0.88%)
Close on Nov 18, 2026Market cap $40.97MP/E –Yield –
Harvard Bioscience EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Harvard Bioscience's EV/EBITDA was 104.7× on Apr 30, 2024, against 88.8× a year earlier. Over the last 5 years it ranged from 27.2× to 963.6×, with a median of 104.9×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Apr 30, 2024 | 104.7× | −122.2 |
| 2023 | Dec 29, 2023 | 226.9× | +103.2 |
| 2022 | Apr 29, 2022 | 123.7× | +18.8 |
| 2021 | Dec 31, 2021 | 104.9× | −284.5 |
| 2020 | Apr 30, 2020 | 389.4× | +57.5 |
| 2019 | Dec 31, 2019 | 331.9× | −40.6 |
| 2016 | Jan 29, 2016 | 372.5× | −57.5 |
| 2015 | Dec 31, 2015 | 430.0× | +380.7 |
| 2014 | Dec 31, 2014 | 49.3× | +30.8 |
| 2013 | Dec 31, 2013 | 18.6× | +8.8 |
| 2012 | Dec 31, 2012 | 9.7× | −1.6 |
| 2011 | Dec 30, 2011 | 11.3× | −1.8 |
| 2010 | Dec 31, 2010 | 13.1× | – |
See a number that looks wrong?